Sen. Tina Smith Sells Off Shares of DexCom, Inc. (NASDAQ:DXCM)

Senator Tina Smith (Democratic-Minnesota) recently sold shares of DexCom, Inc. (NASDAQ:DXCM). In a filing disclosed on May 10th, the Senator disclosed that they had sold between $100,001 and $250,000 in DexCom stock on May 7th.

Senator Tina Smith also recently made the following trade(s):

• Sold $100,001 – $250,000 in shares of Insulet (NASDAQ:PODD) on 5/7/2026.
• Sold $100,001 – $250,000 in shares of DexCom (NASDAQ:DXCM) on 4/29/2026.
• Sold $100,001 – $250,000 in shares of Insulet (NASDAQ:PODD) on 4/29/2026.
• Sold $50,001 – $100,000 in shares of 3M (NYSE:MMM) on 3/31/2026.
• Sold $100,001 – $250,000 in shares of Berkshire Hathaway (NYSE:BRK.B) on 3/31/2026.

DexCom Trading Up 1.3%

DXCM traded up $0.78 on Tuesday, hitting $60.11. The company had a trading volume of 737,418 shares, compared to its average volume of 4,903,241. The business’s fifty day simple moving average is $64.54 and its 200 day simple moving average is $66.16. The company has a quick ratio of 1.64, a current ratio of 1.95 and a debt-to-equity ratio of 0.42. DexCom, Inc. has a 12-month low of $54.11 and a 12-month high of $89.98. The company has a market cap of $23.20 billion, a PE ratio of 25.68, a PEG ratio of 1.04 and a beta of 1.40.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, April 30th. The medical device company reported $0.56 EPS for the quarter, topping analysts’ consensus estimates of $0.47 by $0.09. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The firm had revenue of $1.19 billion during the quarter, compared to analysts’ expectations of $1.17 billion. During the same quarter in the previous year, the business earned $0.32 EPS. The company’s quarterly revenue was up 15.0% on a year-over-year basis. Equities research analysts expect that DexCom, Inc. will post 2.56 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on DXCM shares. Piper Sandler restated an “overweight” rating on shares of DexCom in a report on Thursday, February 5th. Sanford C. Bernstein set a $77.00 price objective on shares of DexCom in a research note on Friday, May 1st. Citigroup reaffirmed a “buy” rating and set a $79.00 target price (down from $84.00) on shares of DexCom in a research note on Monday, May 4th. TD Cowen dropped their price objective on DexCom from $84.00 to $75.00 and set a “buy” rating for the company in a report on Friday, May 1st. Finally, Morgan Stanley reiterated an “overweight” rating on shares of DexCom in a research note on Monday, January 12th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $83.22.

Insider Buying and Selling at DexCom

In related news, EVP Michael Jon Brown sold 1,700 shares of the stock in a transaction that occurred on Wednesday, April 15th. The shares were sold at an average price of $63.04, for a total value of $107,168.00. Following the completion of the transaction, the executive vice president directly owned 111,204 shares of the company’s stock, valued at $7,010,300.16. This trade represents a 1.51% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.28% of the company’s stock.

Institutional Trading of DexCom

Several hedge funds and other institutional investors have recently bought and sold shares of DXCM. Gradient Investments LLC lifted its holdings in shares of DexCom by 13.8% during the 4th quarter. Gradient Investments LLC now owns 332,006 shares of the medical device company’s stock valued at $22,035,000 after purchasing an additional 40,343 shares during the last quarter. Nordea Investment Management AB increased its position in DexCom by 118.6% during the 4th quarter. Nordea Investment Management AB now owns 254,315 shares of the medical device company’s stock valued at $16,988,000 after buying an additional 137,986 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in DexCom by 11.2% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 212,045 shares of the medical device company’s stock valued at $14,269,000 after buying an additional 21,352 shares during the last quarter. NEOS Investment Management LLC raised its stake in DexCom by 58.7% in the third quarter. NEOS Investment Management LLC now owns 175,982 shares of the medical device company’s stock valued at $11,842,000 after buying an additional 65,066 shares during the last quarter. Finally, Peterson Wealth Services boosted its holdings in DexCom by 423.6% in the third quarter. Peterson Wealth Services now owns 28,937 shares of the medical device company’s stock worth $1,947,000 after acquiring an additional 23,410 shares in the last quarter. Institutional investors own 97.75% of the company’s stock.

About Senator Smith

Tina Smith (Democratic Party) is a member of the U.S. Senate from Minnesota. She assumed office on January 3, 2018. Her current term ends on January 3, 2027. Smith (Democratic Party) ran for re-election to the U.S. Senate to represent Minnesota. She won in the general election on November 3, 2020. Smith succeeded former Senator Al Franken (D). She assumed office on January 3, 2018. Smith won a full term in the special general election for the position on November 6, 2018. She defeated Karin Housley (R), Sarah Wellington (Legal Marijuana Now Party), and Jerry Trooien (Unaffiliated) to win the seat. She advanced to the general election after defeating five challengers in the special Democratic primary election on August 14, 2018. Smith previously served as the 48th lieutenant governor of Minnesota. She was elected to the position on a joint ticket with incumbent Governor Mark Dayton on November 4, 2014, and was sworn into office on January 5, 2015.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.